This is a StreetInsider.com Premium Only Page

Cortexyme (CRTX) – StreetInsider.com Reports

Jul 22, 2022 04:30 PM Cortexyme (CRTX) Announces Resignation of EVP of Research and Development

May 20, 2022 08:02 AM Cortexyme (CRTX) Appoints Philip Low to Its Board

May 11, 2022 06:08 AM Cortexyme Inc. (CRTX) PT Lowered to $3.50 at Credit Suisse

May 10, 2022 08:00 AM Cortexyme (CRTX) to Acquire Novosteo

Mar 15, 2022 08:07 AM Cortexyme (CRTX) Appoints Marwan Sabbagh to its Board

Mar 9, 2022 08:06 AM Cortexyme (CRTX) Announces Preclinical Data Highlighting Potential Therapeutic Benefits of Atuzaginstat for the Treatment of High-Risk Oral Potentially Malignant Disorders

Mar 9, 2022 06:27 AM Cortexyme Inc. (CRTX) PT Lowered to $15 at H.C. Wainwright

Mar 8, 2022 08:01 AM Cortexyme (CRTX) Reports Safety and Pharmacokinetics Results from Single Ascending Dose Portion of its Phase 1 Clinical Trial of COR588

Feb 1, 2022 08:05 AM Cortexyme (CRTX) Announces Executive Leadership Team Changes

Feb 1, 2022 08:01 AM Cortexyme (CRTX) Issues Pipeline Update and Anticipated 2022 Milestones

Jan 28, 2022 05:39 AM Canaccord Genuity Downgrades Cortexyme Inc. (CRTX) to Hold

Jan 27, 2022 05:50 AM Cortexyme Inc. (CRTX) PT Lowered to $6 at BofA Securities

Jan 27, 2022 01:27 AM JMP Securities Downgrades Cortexyme Inc. (CRTX) to Market Perform

Jan 26, 2022 08:00 AM Cortexyme (CRTX) Announces Clinical Hold on Atuzaginstat's Investigational New Drug Application

Nov 11, 2021 11:31 AM Cortexyme's (CRTX) Atuzaginstat Slowed Cognitive Decline in Participants With Alzheimer’s Disease and P. Gingivalis Infection in Phase 2/3 GAIN Trial: Additional Top-line Data Presented at CTAD 2021

Nov 11, 2021 05:39 AM Cortexyme Inc. (CRTX) PT Lowered to $2 at Citi

Nov 3, 2021 03:57 AM Increasing unusual call option volume: CHGG IAA MARK CRTX INCY LOTZ

Nov 1, 2021 03:50 AM Stocks with Implied Volatility Movement

Oct 28, 2021 04:33 AM Increasing unusual call option volume: CRTX MARK RBAC IMGN ACAD DT

Oct 27, 2021 09:58 AM Increasing unusual put option volume: CRTX WE BKRT SEAH

Oct 27, 2021 09:29 AM Pre-Open Stock Movers 10/27: (ENPH) (TENB) (FFIV) Higher; (CRTX) (HOOD) (TXN) Lower (more...)

Oct 27, 2021 07:11 AM Cortexyme Inc. (CRTX) PT Lowered to $75 at Canaccord Genuity

Oct 27, 2021 06:03 AM BofA Securities Downgrades Cortexyme Inc. (CRTX) to Underperform

Oct 27, 2021 05:56 AM Cortexyme Inc. (CRTX) PT Lowered to $5 at Citi

Oct 26, 2021 06:16 PM After-Hours Stock Movers 10/26: (TENB) (JNPR) (TWTR) Higher; (CRTX) (HOOD) (ZIOP) Lower (more...)

Oct 26, 2021 04:14 PM Cortexyme (CRTX) 643-participant study in mild to moderate patients with Alzheimer’s disease did not meet statistical significance in its co-primary cognitive and functional endpoints

Oct 26, 2021 04:00 PM Cortexyme (CRTX) Halted, News Pending

Oct 21, 2021 04:30 AM Cortexyme (CRTX) puts more active than calls into data

Oct 19, 2021 01:57 PM Cortexyme (CRTX) option implied volatility elevated

Oct 19, 2021 04:16 AM Increasing unusual put option volume: JNK PROG CRTX ICLN HIMX ERIC

Oct 12, 2021 11:00 AM Cortexyme (CRTX) options active into release of study

Oct 11, 2021 10:57 AM Cortexyme (CRTX) call put ratio 1 call to 2.4 puts into event

Oct 11, 2021 05:11 AM Cortexyme (CRTX) November IV elevated

Oct 8, 2021 12:54 PM Cortexyme (CRTX) November option implied volatility elevated

Sep 27, 2021 07:32 AM Cortexyme (CRTX) on 'Negative Catalyst Watch' at Citi

Sep 16, 2021 07:36 AM Cortexyme Inc. (CRTX) PT Doubles to $150 at Canaccord Genuity

Aug 25, 2021 08:01 AM Cortexyme (CRTX) Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzheimer’s Disease at Annual Biomarkers for Alzheimer’s Disease Summit

Aug 9, 2021 03:30 PM Cortexyme Inc. (CRTX) PT Raised to $96 at JMP Securities, Following Earnings, Business Update

Jul 21, 2021 08:11 AM Cortexyme (CRTX) Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR

Jun 18, 2021 05:43 AM Cortexyme Inc. (CRTX) PT Raised to $58 at BofA Securities

Apr 26, 2021 06:39 AM Credit Suisse Assumes Cortexyme Inc. (CRTX) at Underperform

Mar 5, 2021 06:52 AM Companies with NDRs 3/05

Feb 17, 2021 04:42 AM Jefferies Downgrades Cortexyme Inc. (CRTX) to Hold

Feb 16, 2021 06:27 AM Cortexyme (CRTX) Reports Partial Clinical Hold on Development Program for Atuzaginstat in Alzheimer’s

Dec 11, 2020 08:47 AM Citi Starts Cortexyme Inc. (CRTX) at Sell on Tough Setup

Dec 4, 2020 05:01 PM BofA Securities Upgrades Cortexyme Inc. (CRTX) to Buy

Dec 4, 2020 07:01 AM Cortexyme (CRTX) Reports Phase 2/3 GAIN Trial of Atuzaginstat (COR388) in Patients with Alzheimer’s Disease Successfully Advances Past Interim Analysis

Sep 24, 2020 08:04 AM Cortexyme (CRTX) Announces GAIN Trial of Atuzaginstat in Alzheimer’s Disease Has Exceeded Study Enrollment Target of 570 Patients

Aug 27, 2020 08:01 AM Cortexyme (CRTX) Announces Issuance of Composition of Matter Patent for Atuzaginstat by the U.S. Patent and Trademark Office

Jun 24, 2020 06:51 AM UPDATE: H.C. Wainwright Starts Cortexyme Inc. (CRTX) at Buy